Evidence map›Paper›PMID 39605432›Full record

ArticlebioRxiv : the preprint server for biology2024

Identification of Novel Modulators of the ALT Pathway Through a Native FISH-Based Optical Screen.

Benura Azeroglu, Simran Khurana, Shih-Chun Wang, Gianna M Tricola, Shalu Sharma, Camille Jubelin, Ylenia Cortolezzis, Gianluca Pegoraro, Kyle M Miller, Travis H Stracker and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Benura AzerogluLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0001-7243-384X
Simran KhuranaRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shih-Chun WangDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Gianna M TricolaLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Shalu SharmaRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Camille JubelinLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Ylenia CortolezzisDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Gianluca PegoraroHigh-Throughput Imaging Facility, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0003-2843-9464
Kyle M MillerDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Travis H StrackerRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Eros Lazzerini DenchiLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0001-5378-4644

Funding

HiTIF Microscopy Core FacilityZICBC011567 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PEGORARO, GIANLUCA · 2014 to 2025
$15.8M
Tousled like kinase signaling in cancerZIABC012010 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STRACKER, TRAVIS · 2020 to 2025
$5.7M
Investigate the mechanism of action of the novel telomere length regulator TZAPZIABC011815 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LAZZERINI DENCHI, EROS · 2018 to 2025
$4.7M
Shaping DNA Damage Response Networks Via Histone H2A VariantsR01CA198279 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI Kyle M Miller · 2016 to 2026
$3.3M
Mechanisms of Endogenous DNA Damage PromotionR01CA250905 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MILLER, KYLE M, ROSENBERG, SUSAN M · 2020 to 2024
$3.3M
Intramural NIH HHS ZIA BC011815Intramural NIH HHS ZIA BC012010Intramural NIH HHS ZIC BC011567NCI NIH HHS R01 CA198279NCI NIH HHS R01 CA250905
6 · The paper itself

Abstract

A significant portion of human cancers utilize a recombination-based pathway, Alternative Lengthening of Telomeres (ALT), to extend telomeres. To gain further insights into this pathway, we developed a high-throughput imaging-based screen named TAILS (Telomeric ALT

Indexed as

ALTDDX39Ahistone depositionssTelotelomeres

Identifiers

PMID39605432
PMCPMC11601530

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.